Wall Street analyst estimates for GeoVax Labs, Inc. (GOVX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.86 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-1.09 | ||
| 2026-07-27 | $-0.97 | $-2.16 | +55.1% |
| 2026-05-14 | $-2.62 | $-1.60 | -63.7% |
| 2026-04-02 | $-2.29 | $-4.71 | +51.3% |
| 2025-11-13 | $-7.75 | $-5.85 | -32.4% |
| 2025-07-28 | $-8.75 | $-8.69 | -0.7% |
| 2025-05-01 | $-11.25 | $-14.75 | +23.7% |
| 2025-03-27 | $-7.50 | $-19.75 | +62.0% |
Valuation Ratios
| Price / Book | 1.05 |
| EV / EBITDA | -0.09 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $828918 | $1.1M | $963000 | $1.2M | $1.8M | $385501 | $81526 | 0 | $4.0M | $2.5M |
| Cost of Revenue | $2.0M | $2.0M | $1.9M | 0 | 0 | $15.6M | $9.1M | $20.7M | $95368 | $18.1M |
| Gross Profit | -$1.1M | -$942080 | -$915652 | $1.2M | $1.8M | -$15.2M | -$9.0M | -$20.7M | $3.9M | -$15.6M |
| Research & Development | $2.0M | $2.0M | $1.9M | $1.9M | $2.4M | $15.6M | $9.1M | $20.7M | $23.7M | $18.1M |
| Selling, General & Admin | $2.1M | $1.2M | $1.6M | $1.6M | $2.2M | $3.6M | $5.0M | $5.9M | $5.4M | $6.0M |
| Operating Expenses | $4.1M | $3.2M | $3.5M | $3.5M | $4.6M | $3.6M | $5.0M | $6.0M | $29.0M | $6.0M |
| Operating Income | -$3.3M | -$2.2M | -$2.6M | -$2.4M | -$2.8M | -$18.7M | -$14.0M | -$26.7M | -$25.1M | -$21.6M |
| EBITDA | -$3.2M | -$2.1M | -$2.5M | -$2.4M | -$2.8M | -$18.5M | -$14.0M | -$25.9M | -$24.9M | -$21.4M |
| Interest Expense | 0 | 0 | $2590 | $4495 | $143524 | $1286 | 0 | 0 | $21375 | 0 |
| Pre-tax Income | -$3.3M | -$2.2M | -$2.6M | -$2.4M | -$3.0M | -$18.6M | -$14.0M | -$26.0M | -$25.0M | -$21.5M |
| Income Tax | 0 | 0 | $5213 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$3.3M | -$2.2M | -$2.6M | -$2.4M | -$3.0M | -$18.6M | -$14.0M | -$26.0M | -$25.0M | -$21.5M |
| EPS | $-32.25 | $-21.25 | $-25.25 | $-23.50 | $-29.00 | $-182.50 | $-138.00 | $-255.50 | $-120.50 | $-22.40 |
| EPS (Diluted) | $-32.25 | $-21.25 | $-25.25 | $-23.50 | $-29.00 | $-182.50 | $-138.00 | $-255.50 | $-120.50 | $-22.40 |
| Shares Outstanding (Diluted) | $101595 | $101595 | $101595 | $101595 | $101595 | $101595 | $101595 | $101595 | $207482 | $958443 |
Price
| Price | $0.41 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADAP · ADTX · AIMD · ANL · APLM · BLRX · ICU
Explore sector: Healthcare · Biotechnology
More sections of GOVX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks